Mutations in the TSC1/TSC2 genes lead to activation of the mammalian target of rapamycin (mTOR) signaling pathway, which is the molecular basis for the clinical application of mTOR pathway inhibitors for the treatment of PEComa. The gene discussed is MTOR; the disease is neoplasm with perivascular epithelioid cell differentiation.